Not Yet RecruitingNot Applicable

Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy

Spain10 participantsStarted 2024-05-01

Plain-language summary

This is a prospective observational study to evaluate the phenotype of 10 patients under 10 years of age with developmental epileptic encephalopathy due to mutation of the STXBP1 gene. The study will consist of a clinical and neurodevelopmental evaluation, magnetic resonance imaging, prolonged electroencephalogram, cardiological study, and analysis of biomarkers in cerebrospinal fluid. These patients will be followed up for 3 years. The aim of the study is, knowing the baseline phenotype, to analyse the response to commonly used drugs and to anticipate the response to different drugs available on the market in this group of patients based on clinical and biomarker assessment (EEG, MRI and study of specific proteins and neurotransmitters in plasma, urine and CSF).

Who can participate

Age range1 Month – 10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients under 10 years of age with confirmed mutation for STXBP1. In cases where the diagnostic technique for the mutation is not optimal, a trio exome will be performed to confirm the mutation. Exclusion Criteria: * Presence of functional disability that prevents the neuropsychological study from being carried out and absence of a reliable informant for the patient.

What they're measuring

CSF biomarkers

Timeframe: Baseline, 1 year and 2 years

EEG markers

Timeframe: Baseline, 1 year and 2 years

MRI markers

Timeframe: Baseline, 1 year and 2 years

Trial details

NCT IDNCT06356233

SponsorFundación Iniciativa para las Neurociencias (FINCE)

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-10-01

View on ClinicalTrials.gov More STXBP1 Encephalopathy With Epilepsy trials